Yihui Pharmaceutical

Shanghai Yihui Pharmaceutical Technology is a clinical-stage biotechnology company based in China that focuses on the discovery and development of innovative small molecule drugs. The company specializes in Targeted Protein Degradation (TPD) and PROTAC technologies to address high-value targets in oncology and immunology that are often considered undruggable by traditional methods. Its lead programs include novel degraders and inhibitors designed to treat B-cell malignancies and various solid tumors. Yihui has established a robust proprietary platform for the rapid identification and optimization of protein degraders. The company is backed by prominent venture capital firms and aims to provide transformative therapies for patients with significant unmet medical needs.